CRDF — Cardiff Oncology Income Statement
0.000.00%
Last trade - 00:00
- $181.97m
- $106.08m
- $0.49m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.245 | 0.366 | 0.359 | 0.386 | 0.488 |
Cost of Revenue | |||||
Gross Profit | 0.245 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.9 | 19.5 | 29.2 | 40.3 | 45.9 |
Operating Profit | -16.7 | -19.1 | -28.9 | -39.9 | -45.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16.4 | -19.3 | -28.3 | -38.7 | -41.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.4 | -19.3 | -28.3 | -38.7 | -41.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.4 | -19.3 | -28.3 | -38.7 | -41.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.7 | -22.6 | -28.3 | -38.7 | -41.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.8 | -1.08 | -0.725 | -0.888 | -0.928 |